On the afternoon of September 11, on the banks of the beautiful Huangpu River, nearly 150 experts and scholars in China's cardiovascular field "gathered together" in the form of "offline joint online" to conduct extensive and in-depth discussions on the launching of the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" version 2.0 - "Musk Heart Pills for the Treatment of Coronary Heart Disease Expert Consensus".
Professor Wu Zonggui
Professor Wu Zonggui of the Long March Hospital Affiliated to the Naval Military Medical University presided over the meeting as the chairman of the conference, and well-known experts such as Academician Chen Keji of Xiyuan Hospital of China Academy of Chinese Medical Sciences, Professor Shi Haiming of Huashan Hospital Affiliated to Fudan University, Professor Cai Yisheng of Zhongshan Hospital Affiliated to Fudan University, and President Zhou Junjie of Shanghai Hehuang Pharmaceutical Industry attended the kick-off meeting.
<h1 class="pgc-h-arrow-right" data-track="37" > the "Musk Heart Pills Treatment Of Coronary Heart Disease Expert Consensus" was launched: it is opportune and stick to the original intention</h1>
Chen Keji Academician
At the beginning of the meeting, Academician Chen Keji pointed out that traditional Chinese medicine has a long history in the treatment of coronary heart disease, and as a representative drug for the treatment of coronary heart disease by integrated traditional Chinese and Western medicine, musk baoxin pill has accumulated nearly 40 years of application experience. In 2018, the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" was officially released, which played an important role in standardizing and guiding the clinical application of Musk Heart Pills. In recent years, more high-quality research evidence of musk pills has been published, especially the MUST study published in the Chinese Medical Journal (Chinese Medical Journal English Edition) earlier this year, which confirms the clinical value of musk pills. It is believed that this time, the National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine and the Cardiovascular Disease Professional Committee of the Branch of Integrative Traditional Chinese and Western Medicine of the Chinese Medical Doctor Association will jointly promote the renewal of the consensus, which will better promote the standardized use of musk baoxin pills and exert its clinical value.
Zhou Junjie President
President Zhou Junjie said in his speech that in recent years, the Party Central Committee and the State Council have put forward the strategic goal of promoting the development of traditional Chinese medicine, and General Secretary Xi Jinping has repeatedly made important instructions on the development and innovation of traditional Chinese medicine, which is a great encouragement for the development of traditional Chinese medicine. Since its establishment 20 years ago, Shanghai Hehuang Pharmaceutical has always adhered to the modernization and international development of traditional Chinese medicine, and musk baoxin pill is one of the representative drugs. From winning the second prize of the National Science and Technology Progress Award in 2018 to the official publication of THE EVIDENCE-based research results of MUST in 2021, Musk Baoxin Pill has embarked on an evidence-based road of inheritance and development from evidence-based evidence to clinical application. It is hoped that the "Expert Consensus on the Treatment of Coronary Heart Disease by Musk Heart Pills" will help clinicians apply Musk Heart Pills better and more standardized in the future to benefit more patients.
<h1 class="pgc-h-arrow-right" data-track="41" > "Musk Heart Pills for Coronary Heart Disease Expert Consensus": improve evidence-based evidence and focus on clinical applications</h1>
Under the guidance of Professor Dai Ruihong of Huashan Hospital affiliated to Fudan University, Academician Chen Keji of the Chinese Academy of Sciences, Academician Zhang Boli of the Chinese Academy of Engineering, and Academician Gao Runlin of the Chinese Academy of Engineering, the writing of the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" was launched in 2016 and officially published in 2018, which systematically reviewed and summarized the pharmacological effects, clinical efficacy and safety evidence of musk baoxin pills.
Since 2017, evidence-based evidence for the treatment of coronary heart disease by musk pills has continued to emerge, including 491 new articles in Chinese journals, 19 journals in the Chinese Medical Association, 36 articles in English journals, and 18 articles with an impact factor of > 3 points. In addition, musk heart pills have been included in more than ten guidelines/consensus to recommend drugs for the treatment of coronary heart disease. In view of this, in order to better support clinical practice with evidence-based evidence, the launch of the "Expert Consensus on the Treatment of Coronary Heart Disease with Musk Heart Pills" is imminent. At the meeting, Professor Shi Haiming introduced the main points of this consensus update.
Professor Shi Haiming
Professor Shi Haiming particularly pointed out that the increasing amount of evidence-based evidence, especially the release of MUST studies, provides a solid foundation for the clinical application of musk heart pills in the treatment of coronary heart disease. Based on these new evidences, this consensus update will organize cardiovascular traditional Chinese and Western medicine experts across the country to collect and discuss opinions extensively and deeply, and the process of writing and revision will take 6 months, and it is expected that in April 2022, the "Musk Baoxin Pill Treatment of Coronary Heart Disease Expert Consensus" will be officially released.
<h1 class="pgc-h-arrow-right" data-track="44" > MUST Research: Sharpen the sword for ten years, and now will be tried</h1>
In the discussion session, experts and scholars from all over the country recognized and affirmed the consensus update. Experts mentioned that as the largest clinical study of traditional Chinese medicine in line with international norms, the MUST study took cardiac and cerebrovascular events as the main research endpoint, and proved the clinical value of musk heart pills through rigorous research design and scientific clinical data. In this consensus update, MUST research should be highlighted, so as to provide guidance and reference for the future development of evidence-based research in traditional Chinese medicine.
MUST Research: Evidence-based research on TCM that meets international norms
The MUST study, led by Academician Ge Junbo of Zhongshan Hospital affiliated to Fudan University and Professor Fan Weihu of Huashan Hospital affiliated to Fudan University, is a multicenter, randomized, double-blind, placebo-controlled Phase IV clinical trial, and all endpoint events were independently reviewed by the endpoint event review committee led by Academician Chen Keji.
The study covered 22 provinces, municipalities directly under the central government and autonomous regions across the country, with a total of 97 tertiary hospitals participating, a total of 2673 CAD patients were included, and 8 follow-up visits were completed, lasting 24 months. The study's observational indicators covered the "hard endpoint" major cardiovascular adverse events (MACE) and the "soft endpoint" Seattle angina Scale (SAQ), which was registered as a clinical trial in China and the United States.
MUST study results: safe and effective for long-term application
The results showed that in terms of MACE, the incidence of MACE after 2 years of treatment in the experimental group (musk heart pills combined with standard therapy) and the control group (placebo combined standard therapy) was 1.9% and 2.6%, respectively. Among them, the K-M curve was gradually separated after 18 months, and the incidence of MACE in the experimental group was reduced by 26.9% compared with the control group at 24 months, which suggested the characteristics of the long-term effect of musk heart pills and provided strong support for the long-term treatment of coronary heart disease by musk heart pills. In addition, subgroup analysis showed that the use of musk heart pills in women and patients with a BMI of < 24 kg/㎡ significantly reduced the risk of MACE events, indicating that musk heart pills benefited more in women and BMI < 24 kg/㎡ populations.
In terms of saq, the secondary study endpoint, the results showed that long-term use of musk heart pills could significantly improve the stability and frequency of attacks of angina in patients, indicating that musk heart pills could effectively alleviate patients' symptoms and significantly improve patients' quality of life. In terms of safety endpoints, studies confirmed that the incidence of liver and kidney function and metabolism-related adverse events related to long-term use of musk pills was comparable to that of the control group, indicating that the long-term use of musk pills was safe.
<h1 class="pgc-h-arrow-right" data-track="46" > summary</h1>
From the advent of small pills in 1981, to the official release of the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" in 2018, to the national science and technology progress award in 2019, to the fact that the MUST research results were honored in the Chinese Medical Journal (Chinese Medical Journal English Edition) in January 2021, and then to the launch of the "Musk Heart Pills for the Treatment of Coronary Heart Disease Expert Consensus" in September 2021, the research of Musk Heart Pills has always adhered to modernization. International development strategy and goals, step by step. It is expected that with the advent of the "Musk Heart Pills For the Treatment of Coronary Heart Disease Expert Consensus" in the future, the clinical application of Musk Heart Pills will be more standardized and scientific, benefiting more patients with coronary heart disease.